These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 38008609)

  • 61. Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease.
    Xie C; Liu K; Xie Y; Liu S; Ji B
    Clin Res Hepatol Gastroenterol; 2024 Feb; 48(2):102264. PubMed ID: 38142587
    [TBL] [Abstract][Full Text] [Related]  

  • 62. New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice.
    Canivet CM; Boursier J; Loomba R
    Semin Liver Dis; 2024 Feb; 44(1):35-42. PubMed ID: 38531378
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project.
    Nabrdalik K; Kwiendacz H; Irlik K; Hendel M; Drożdż K; Wijata AM; Nalepa J; Janota O; Wójcik W; Gumprecht J; Lip GYH
    Cardiovasc Diabetol; 2023 Nov; 22(1):318. PubMed ID: 37985994
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prevalence, proportions of elevated liver enzyme levels, and long-term cardiometabolic mortality of patients with metabolic dysfunction-associated steatotic liver disease.
    Chen YT; Chen TI; Yin SC; Huang CW; Huang JF; Lu SN; Yeh ML; Huang CF; Dai CY; Chen YW; Chuang WL; Yu ML; Lee MH
    J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38725327
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dietary characteristics associated with the risk of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease in non-obese Japanese participants: A cross-sectional study.
    Taniguchi H; Ueda M; Sano F; Kobayashi Y; Shima T
    JGH Open; 2024 May; 8(5):e13082. PubMed ID: 38779132
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Usefulness of a questionnaire for assessing the relationship between eating behavior and steatotic liver disease among Japanese male young adults.
    Miwa T; Tajirika S; Hanai T; Imamura N; Adachi M; Horita R; Fukao T; Shimizu M; Yamamoto M
    Sci Rep; 2024 Jan; 14(1):2194. PubMed ID: 38273030
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum.
    Vidal-Cevallos P; Sorroza-Martínez AP; Chávez-Tapia NC; Uribe M; Montalvo-Javé EE; Nuño-Lámbarri N
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673981
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Intra-gastric balloon with lifestyle modification: a promising therapeutic option for overweight and obese patients with metabolic dysfunction-associated steatotic liver disease.
    van Dijk AM; de Vries M; El-Morabit F; Bac ST; Mundt MW; van der Schuit LE; Hirdes MMC; Kara M; de Bruijne J; van Meer S; Kaasjager HAH; de Valk HW; Vleggaar FP; van Erpecum KJ
    Intern Emerg Med; 2023 Nov; 18(8):2271-2280. PubMed ID: 37700180
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations.
    Polyzos SA; Kechagias S; Tsochatzis EA
    Aliment Pharmacol Ther; 2021 Oct; 54(8):1013-1025. PubMed ID: 34416040
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Increased visceral fat area to skeletal muscle mass ratio is positively associated with the risk of metabolic dysfunction-associated steatotic liver disease in a Chinese population.
    Liu C; Li N; Sheng D; Shao Y; Qiu L; Shen C; Liu Z
    Lipids Health Dis; 2024 Apr; 23(1):104. PubMed ID: 38616253
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The Impact of Metabolic Bariatric Surgery on Cardiovascular Diseases in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Esparham A; Shoar S; Mehri A; Khorgami Z; Modukuru VR
    Obes Surg; 2024 Jul; 34(7):2338-2346. PubMed ID: 38662250
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study.
    Masarone M; Motta BM; Torre P; Aquino M; Belladonna F; Lombardi M; Troisi J; Persico M
    Intern Emerg Med; 2024 May; ():. PubMed ID: 38753115
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Metabolic disease and the liver: A review.
    Vargas M; Cardoso Toniasso SC; Riedel PG; Baldin CP; Dos Reis FL; Pereira RM; Brum MCB; Joveleviths D; Alvares-da-Silva MR
    World J Hepatol; 2024 Jan; 16(1):33-40. PubMed ID: 38313243
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome.
    Xu Q; Zhang J; Lu Y; Wu L
    iScience; 2024 Feb; 27(2):108783. PubMed ID: 38292434
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes-Interventional Study.
    Hachuła M; Kosowski M; Basiak M; Okopień B
    Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37764998
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease.
    Armandi A; Bugianesi E
    Eur J Intern Med; 2024 Apr; 122():20-27. PubMed ID: 38262842
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease.
    Jimenez Ramos M; Kendall TJ; Drozdov I; Fallowfield JA
    Ann Hepatol; 2024; 29(2):101278. PubMed ID: 38135251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.